Back to top
more

Endocyte, Inc. (ECYT)

(Delayed Data from NSDQ)

$23.99 USD

23.99
NA

0.00 (0.00%)

Updated Dec 20, 2018 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Sanghamitra Saha headshot

What Downbeat 2018? These 5 Top Stocks Are Up More Than 100%

These five stocks gained more than 100% defying the market sluggishness this year.

    Zacks.com highlights: Baytex Energy, Capstone Turbine, Endocyte, First BanCorp and FuelCell

    Zacks.com highlights: Baytex Energy, Capstone Turbine, Endocyte, First BanCorp and FuelCell

      Kevin Matras headshot

      Explosive Stocks Under $10

      Kevin Matras looks for stocks under $10 with explosive potential. Highlighted stocks include BTE, CPST, ECYT, FBP and FCEL.

        Zacks.com highlights: Stoneridge, FGL Holdings, Lindblad Expeditions Holdings, Endocyte and Knoll

        Zacks.com highlights: Stoneridge, FGL Holdings, Lindblad Expeditions Holdings, Endocyte and Knoll

          New Analyst Coverage Puts Spotlight on 5 Stocks

          More analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.

            Endocyte (ECYT) Catches Eye: Stock Jumps 7.7%

            Endocyte (ECYT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

              Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4

              Endocyte, Inc. (ECYT) posts wider-than-expected loss in the fourth quarter of 2017. The company finalized a phase III VISION trial design for 177Lu-PSMA-617 following a successful End of Phase II meeting with the FDA.

                Endocyte (ECYT) Posts Wider than Expected Loss in Q4

                Endocyte???s fourth-quarter 2017 loss was wider-than-expected.

                  What's in Store for Endocyte (ECYT) This Earnings Season?

                  Endocyte (ECTY) is expected to provide updates on its pipeline candidates EC1169 and EC2629 during the fourth quarter 2017 earnings call on Feb 26.

                    Options Traders Expect Huge Moves in Endocyte (ECYT) Stock

                    Investors in Endocyte (ECYT) need to pay close attention to the stock based on moves in the options market lately.

                      Options Traders Expect Huge Moves in Endocyte (ECYT) Stock

                      Surging implied volatility makes Endocyte (ECYT) stock lucrative to the option traders.

                        Endocyte (ECYT) Posts Narrower-than-Expected Q3 Loss

                        Endocyte (ECYT) posted narrower-than-expected loss in the third quarter of 2017. The company will focus on the development of PSMA-617 that it licensed in the same quarter.

                          Will Endocyte (ECYT) Disappoint This Earnings Season?

                          Endocyte (ECYT) plans to focus on its most promising programs like CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform and its pipeline candidate EC2629 in Q3.

                            Endocyte Inks Deal For Prostate Cancer Candidate, Shares Up

                            Endocyte (ECYT) acquired an exclusive worldwide license to develop and commercialize ABX GmbH's phase III-ready prostate cancer candidate 177Lu-PSMA-617.

                              Options Traders Expect Huge Moves in Endocyte (ECYT) Stock

                              Endocyte (ECYT) needs Investors to pay close attention to the stock based on moves in the options market lately.

                                Endocyte (ECYT) Stock Up Despite Wider-than-Expected Q2 Loss

                                Endocyte (ECYT) second quarter loss was wider than expected. The company has announced restructuring initiatives to shift its pipeline focus to CAR-T cell platform.

                                  Spectrum (SPPI) Q2 Loss Narrower than Expected, Sales Beat

                                  Spectrum Pharmaceuticals. (SPPI) reported narrower than expected sales and also beat sales expectations. The shares of the company were up due to positive pipeline updates.

                                    Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View

                                    Shire plc (SHPG) product sales soared in the second quarter on the back of legacy Baxalta sales. However, generic competition is expected to negatively impact full year revenues.

                                      What's in Store for Endocyte (ECYT) this Earnings Season?

                                      Endocyte (ECYT) looks forward to shift its focus on CAR T-cell small-molecule drug conjugates (SMDCs) adaptor platform, the dual-targeted DNA crosslinker drug EC2629 in Q2.

                                        Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform

                                        We issued an updated research report Endocyte, Inc. (ECYT) on Jul 12.

                                          Walgreens (WBA) to Report Q3 Earnings: What's in Store?

                                          Walgreens Boots Alliance, Inc. (WBA) is slated to release third-quarter fiscal 2017 results before the market opens on Jun 29.

                                            Why Is Endocyte (ECYT) Down 37.9% Since the Last Earnings Report?

                                            Endocyte (ECYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                              Endocyte (ECYT) Focused on Two Lead Pipeline Candidates

                                              We issued an updated report on Endocyte, Inc. (ECYT) on May 17.

                                                Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1

                                                Endocyte, Inc. (ECYT) reported a narrower-than-expected loss in the first quarter of 2017.

                                                  Endocyte (ECYT) Reports Narrower than Expected Q1 Loss

                                                  Endocyte reported a loss per share of 27 cents per share while our consensus called for a loss of 28 cents per share.